Repair Biotechnologies
Repair Biotechnologies is a biotechnology company focused on developing therapies to reverse atherosclerosis and other conditions driven by excess cholesterol. Their innovative Cholesterol Degrading Platform (CDP) aims to rapidly and safely reduce plaque in arteries, addressing a major cause of cardiovascular disease and mortality. The company is also exploring treatments for related diseases such as liver fibrosis and metabolic disorders, with a mission to significantly improve human healthspan by targeting the root causes of age-related diseases.
Industries
Nr. of Employees
small (1-50)
Repair Biotechnologies
841 East Fayette St, Syracuse, NY 13210
Products
Cholesterol Degrading Platform (CDP)
A modular therapeutic platform that enables cells to degrade excess intracellular free cholesterol via expression of engineered catabolic proteins; intended for use across indications driven by localized cholesterol accumulation.
REP-0003 (CDP mRNA-LNP program for HoFH / atherosclerosis)
An mRNA-LNP therapeutic program developed using the Cholesterol Degrading Platform, aimed at reducing aortic plaque burden in homozygous familial hypercholesterolemia and broader atherosclerosis indications.
Cholesterol Degrading Platform (CDP)
A modular therapeutic platform that enables cells to degrade excess intracellular free cholesterol via expression of engineered catabolic proteins; intended for use across indications driven by localized cholesterol accumulation.
REP-0003 (CDP mRNA-LNP program for HoFH / atherosclerosis)
An mRNA-LNP therapeutic program developed using the Cholesterol Degrading Platform, aimed at reducing aortic plaque burden in homozygous familial hypercholesterolemia and broader atherosclerosis indications.
Services
Non-exclusive collaboration and licensing with external lipid nanoparticle delivery providers to develop LNP-formulated mRNA therapeutic products for atherosclerosis.
Execution of in vitro and in vivo preclinical efficacy studies, histological analysis, functional outcome measurements, and preparation of IND-enabling documentation for regulatory interactions.
Design and optimization of recombinant proteins and gene expression constructs intended to enable intracellular cholesterol catabolism.
In vitro assay development and execution using mammalian cell lines and induced pluripotent stem cell systems to evaluate cell-level efficacy and safety.
Non-exclusive collaboration and licensing with external lipid nanoparticle delivery providers to develop LNP-formulated mRNA therapeutic products for atherosclerosis.
Execution of in vitro and in vivo preclinical efficacy studies, histological analysis, functional outcome measurements, and preparation of IND-enabling documentation for regulatory interactions.
Design and optimization of recombinant proteins and gene expression constructs intended to enable intracellular cholesterol catabolism.
In vitro assay development and execution using mammalian cell lines and induced pluripotent stem cell systems to evaluate cell-level efficacy and safety.
Expertise Areas
- Gene therapy development
- mRNA-LNP therapeutic development
- Preclinical in vivo efficacy studies (cardiovascular and liver models)
- Atherosclerosis and familial hypercholesterolemia therapeutics
Key Technologies
- mRNA with lipid nanoparticle (LNP) delivery
- Adeno-associated virus (AAV) vectors
- Engineered intracellular cholesterol-degrading enzymes
- Recombinant protein engineering